MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/130/0.1/20.09.24 Share Price

Warrant

DE000ME1GBJ3

Market Closed - Börse Stuttgart 10:21:14 05/07/2024 pm IST
1.49 EUR +7.97% Intraday chart for MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/130/0.1/20.09.24
Current month-10.24%
1 month-4.49%
Date Price Change
05/24/05 1.49 +7.97%
04/24/04 1.38 +11.29%
03/24/03 1.24 -20.51%
02/24/02 1.56 -12.36%
01/24/01 1.78 +7.23%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 10:21 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying NOVO NORDISK A/S
Issuer Morgan Stanley
WKN ME1GBJ
ISINDE000ME1GBJ3
Date issued 03/10/2023
Strike 130 $
Maturity 20/09/2024 (77 Days)
Parity 10 : 1
Emission price 0.25
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.89
Lowest since issue 0.175
Delta0.77x
Omega 6.533
Premium3.15x
Gearing8.45x
Moneyness 1.095
Difference Strike -12.37 $
Difference Strike %-9.52%
Spread 0.01
Spread %0.64%
Theoretical value 1.555
Implied Volatility 32.91 %
Total Loss Probability 27.43 %
Intrinsic value 1.141
Present value 0.4139
Break even 146.86 €
Theta-0.04x
Vega0.02x
Rho0.02x

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974 DKK
Average target price
952.2 DKK
Spread / Average Target
-2.24%
Consensus